

Zhen-Yu Ding

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6962902/publications.pdf>

Version: 2024-02-01

73
papers

3,831
citations

471509

17
h-index

138484

58
g-index

78
all docs

78
docs citations

78
times ranked

5324
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <i>Lancet</i> , The, 2019, 393, 1819-1830.	13.7	2,347
2	Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. <i>Nature Medicine</i> , 2020, 26, 732-740.	30.7	322
3	Synthesis and biological evaluation of 4-(1,2,3-triazol-1-yl)coumarin derivatives as potential antitumor agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 799-807.	2.2	126
4	Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 26.	17.1	112
5	Inhibition of FGF α -FGFR and VEGF α -VEGFR signalling in cancer treatment. <i>Cell Proliferation</i> , 2021, 54, e13009.	5.3	76
6	Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management. <i>Frontiers in Pharmacology</i> , 2019, 10, 1350.	3.5	75
7	A Novel Nomogram and Risk Classification System Predicting the Cancer-Specific Survival of Patients with Initially Diagnosed Metastatic Esophageal Cancer: A SEER-Based Study. <i>Annals of Surgical Oncology</i> , 2019, 26, 321-328.	1.5	61
8	Enantioselective Allylic Amination of Morita α -Baylis α -Hillman Carbonates Catalysed by Modified Cinchona Alkaloids. <i>European Journal of Organic Chemistry</i> , 2009, 2009, 5804-5809.	2.4	50
9	Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination With Immune Checkpoint Inhibitors in Cancer Treatment. <i>Frontiers in Pharmacology</i> , 2019, 10, 1184.	3.5	50
10	Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 135-145.	4.2	42
11	Predicting severe acute radiation pneumonitis in patients with non-small cell lung cancer receiving postoperative radiotherapy: Development and internal validation of a nomogram based on the clinical and dose α -volume histogram parameters. <i>Radiotherapy and Oncology</i> , 2019, 132, 197-203.	0.6	33
12	Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study. <i>Lung Cancer</i> , 2016, 96, 93-100.	2.0	32
13	Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma. , 2021, 9, e002836.		31
14	Neutrophil-Lymphocyte Ratio as a Prognostic Marker for Chemotherapy in Advanced Lung Cancer. <i>International Journal of Biological Markers</i> , 2016, 31, 395-401.	1.8	22
15	PD-1 Inhibitors in the Advanced Esophageal Cancer. <i>Frontiers in Pharmacology</i> , 2019, 10, 1418.	3.5	22
16	Concurrent brain radiotherapy and EGFR-TKI may improve intracranial metastases control in non-small cell lung cancer and have survival benefit in patients with low DS-GPA score. <i>Oncotarget</i> , 2017, 8, 111309-111317.	1.8	22
17	Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer. <i>International Immunopharmacology</i> , 2021, 91, 107296.	3.8	20
18	The Ways of Isolating Neoantigen-Specific T Cells. <i>Frontiers in Oncology</i> , 2020, 10, 1347.	2.8	19

#	ARTICLE	IF	CITATIONS
19	Cancer Microenvironment and Cancer Vaccine. <i>Cancer Microenvironment</i> , 2012, 5, 333-344.	3.1	18
20	A phase I trial of PD-1 deficient engineered T cells with CRISPR/Cas9 in patients with advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3050-3050.	1.6	17
21	Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports. <i>Oncotarget</i> , 2017, 8, 49680-49688.	1.8	17
22	Safety and efficacy of radiation and chemoradiation in patients over 70 years old with inoperable esophageal squamous cell carcinoma. <i>Oncology Letters</i> , 2014, 7, 260-266.	1.8	16
23	Special AT-rich sequence binding protein 1 expression correlates with response to preoperative radiotherapy and clinical outcome in rectal cancer. <i>Cancer Biology and Therapy</i> , 2015, 16, 1738-1745.	3.4	16
24	Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer. <i>Disease Markers</i> , 2022, 2022, 1-11.	1.3	16
25	Lung adenocarcinoma with ERBB2 exon 20 insertions: Comutations and immunogenomic features related to chemoimmunotherapy. <i>Lung Cancer</i> , 2021, 160, 50-58.	2.0	14
26	Mannan-modified adenovirus targeting TERT and VEGFR-2: A universal tumour vaccine. <i>Scientific Reports</i> , 2015, 5, 11275.	3.3	13
27	Well-controlled pleural effusion indicated pseudoprogression after immunotherapy in lung cancer: A case report. <i>Thoracic Cancer</i> , 2018, 9, 1190-1193.	1.9	13
28	Pulmonary Lymphoepithelioma-Like Carcinoma Treated with Immunotherapy or Chemotherapy: A Single Institute Experience. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 1073-1081.	2.0	13
29	Viral infections and the efficacy of PD-(L)1 inhibitors in virus-related cancers: Head and neck squamous cell carcinoma and hepatocellular carcinoma. <i>International Immunopharmacology</i> , 2021, 100, 108128.	3.8	13
30	Identification of Epithelial-Mesenchymal Transition- (EMT-) Related LncRNA for Prognostic Prediction and Risk Stratification in Esophageal Squamous Cell Carcinoma. <i>Disease Markers</i> , 2021, 2021, 1-18.	1.3	13
31	Exploring the binding mode of HIV-1 Vif inhibitors by blind docking, molecular dynamics and MM/GBSA. <i>RSC Advances</i> , 2013, 3, 22532.	3.6	11
32	Clinical characteristics of the mixed form of neuroendocrine tumor in the lung: A retrospective study in 2501 lung cancer cases. <i>Thoracic Cancer</i> , 2015, 6, 25-30.	1.9	11
33	Nomogram Personalizes and Visualizes the Overall Survival of Patients with Triple-Negative Breast Cancer Based on the Immune Genome. <i>BioMed Research International</i> , 2020, 2020, 1-16.	1.9	11
34	Prognostic significance of osteopontin expression in non-small-cell lung cancer: A meta-analysis. <i>Molecular and Clinical Oncology</i> , 2015, 3, 633-638.	1.0	10
35	Association of the independent polymorphisms in CDKN2A with susceptibility of acute lymphoblastic leukemia. <i>Bioscience Reports</i> , 2018, 38, .	2.4	10
36	Exploring the selectivity of PI3K and mTOR inhibitors by 3D-QSAR, molecular dynamics simulations and MM/GBSA binding free energy decomposition. <i>MedChemComm</i> , 2013, 4, 1482.	3.4	9

#	ARTICLE	IF	CITATIONS
37	Assessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 816-824.	1.4	9
38	Therapeutic vaccine for melanoma: the untouched grail?. <i>Expert Review of Vaccines</i> , 2007, 6, 907-911.	4.4	8
39	Concurrent paclitaxel-based chemo-radiotherapy for post-surgical microscopic residual tumor at the bronchial margin (R1 resection) in non-small-cell lung cancer. <i>BMC Cancer</i> , 2015, 15, 36.	2.6	7
40	Chemotherapy-induced fatal hepatitis B virus reactivation in a small-cell lung cancer patient. <i>Molecular and Clinical Oncology</i> , 2016, 5, 382-384.	1.0	7
41	Crizotinib versus chemotherapy: a real-world cost-effectiveness study in China. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 93-102.	1.4	7
42	Toxicities of Immunotherapy for Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 603658.	2.8	6
43	Phase II study of oral etoposide maintenance for patients with extensive stage small cell lung cancer who have responded to the induction on an EP regimen. <i>Thoracic Cancer</i> , 2013, 4, 234-240.	1.9	5
44	A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC. <i>Investigational New Drugs</i> , 2020, 38, 478-484.	2.6	5
45	Inferior outcome of bone metastasis in non-small-cell-lung-cancer patients treated with epidermal growth factor receptor inhibitors. <i>Journal of Bone Oncology</i> , 2021, 29, 100369.	2.4	5
46	The best choice of induction chemotherapy for patients with locally advanced nasopharyngeal carcinoma: Bayesian network meta-analysis. <i>Head and Neck</i> , 2022, 44, 518-529.	2.0	5
47	Immunotherapy for a POLE Mutation Advanced Non-Small-Cell Lung Cancer Patient. <i>Frontiers in Pharmacology</i> , 2022, 13, 817265.	3.5	5
48	Systematic Immunological Level Determined the Prognosis of Leptomeningeal Metastasis in Lung Cancer. <i>Cancer Management and Research</i> , 2022, Volume 14, 1153-1164.	1.9	5
49	Safety and efficacy of paclitaxel liposome for elderly patients with advanced non-small cell lung cancer: A multicenter prospective study. <i>Thoracic Cancer</i> , 2013, 4, 14-19.	1.9	4
50	Bone metastasis from lung cancer identified by genetic profiling. <i>Oncology Letters</i> , 2017, 13, 847-850.	1.8	4
51	Comparison of chemotherapy plus bevacizumab vs. chemotherapy alone as third-line treatment or beyond for advanced non-small cell lung cancer: A propensity score-matched analysis. <i>Oncology Letters</i> , 2018, 15, 5671-5679.	1.8	4
52	Orthotopic Transplantation of Cryopreserved Mouse Ovaries and Gonadotrophin Releasing Hormone Analogues in the Restoration of Function following Chemotherapy-Induced Ovarian Damage. <i>PLoS ONE</i> , 2015, 10, e0120736.	2.5	4
53	Pulmonary metastases of fibrosarcomatous dermatofibrosarcoma protuberans respond to apatinib-based angiogenesis and chemotherapy: a case report. <i>Annals of Translational Medicine</i> , 2019, 7, 149-149.	1.7	4
54	Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines. <i>Molecular Biomedicine</i> , 2020, 1, 16.	4.4	4

#	ARTICLE	IF	CITATIONS
55	Progression of Central Nervous System Metastases in Advanced Nonsmall Cell Lung Cancer Patients Effectively Treated with First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2018, 33, 421-426.	1.0	3
56	Major pathological response after neoadjuvant immunotherapy in esophageal spindle cell carcinoma: A case report. <i>Thoracic Cancer</i> , 2021, 12, 1234-1239.	1.9	3
57	Anlotinib-induced acute myocardial infarction: A case report and literature review. <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 3203-3207.	1.8	3
58	Identifying tumor antigens and immune subtyping in colon adenocarcinoma to facilitate the development of mRNA vaccine. <i>Cancer Medicine</i> , 2022, , .	2.8	3
59	Living modulates the apoptotic effects of vesicular stomatitis virus in lung adenocarcinoma. <i>International Journal of Oncology</i> , 2015, 47, 1775-1782.	3.3	2
60	Monitoring the estimated glomerular filtration rate (eGFR) in patients with small-cell lung cancer during chemotherapy: equations based on serum creatinine or cystatin C?. <i>International Journal of Clinical Oncology</i> , 2018, 23, 258-265.	2.2	2
61	Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) impact on immune microenvironment in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, e21154-e21154.	1.6	2
62	Advanced squamous lung carcinoma in a patient experiencing long-term survival following repeated responses to gemcitabine and cisplatin chemotherapy: A case report. <i>Oncology Letters</i> , 2015, 9, 2874-2878.	1.8	1
63	Imaging Pattern of Diffuse Intrapulmonary Metastases in Lung Cancer Was Associated with Poor Prognosis to Epidermal Growth Factor Receptor Inhibitors. <i>Cancer Management and Research</i> , 2020, Volume 12, 11761-11772.	1.9	1
64	Early CT perfusion changes and the outcome of antiangiogenic therapy and chemotherapy in patients with advanced primary lung adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20543-e20543.	1.6	1
65	Neoantigen-based personalized DC vaccine for lung cancer: An update of translational study.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20674-e20674.	1.6	1
66	Clinical characteristics of mixed neuroendocrine cancer of lung: Retrospective analysis of 20 cases from 2,501 lung cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, e19055-e19055.	1.6	0
67	Prognostic significance of protein kinase BAKT pathway in adult adrenocortical carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, e22229-e22229.	1.6	0
68	Relationship of RRM1 compared to ERCC1 gene in peripheral blood to the efficacy of the gemcitabine chemotherapy in advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e23092-e23092.	1.6	0
69	How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitor for lung adenosquamous cell carcinoma harboring EGFR mutation? A bicenter research and pooled analysis of published reports.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20571-e20571.	1.6	0
70	Neoantigen-based personalized, immune cell therapy for patients with advanced NSCLC: A pilot study.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15043-e15043.	1.6	0
71	Identification of Epithelial-Mesenchymal Transition- (EMT-) Related LncRNA for Prognostic Prediction and Risk Stratification in Esophageal Squamous Cell Carcinoma. <i>Disease Markers</i> , 2021, 2021, 5340240.	1.3	0
72	Editorial: The Clinical Application of Neoantigens. <i>Frontiers in Immunology</i> , 2022, 13, 842633.	4.8	0

#	ARTICLE	IF	CITATIONS
73	Linkage of time interval from neoadjuvant chemoradiotherapy to surgery with pathological response and survival profile in resectable esophageal cancer patients.. Journal of Clinical Oncology, 2022, 40, e16071-e16071.	1.6	0